"instanceType","rationale","uuid:ID","name","id","description","label"
"StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ad15341b-0a1d-447d-b5aa-1602ea94a3e7","Study Design 1","StudyDesign_1","The main design for the study",""
